Brokerages expect Sientra Inc (NASDAQ:SIEN) to report earnings of ($0.43) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Sientra’s earnings, with estimates ranging from ($0.47) to ($0.38). Sientra reported earnings per share of ($0.86) during the same quarter last year, which would indicate a positive year over year growth rate of 50%. The firm is expected to issue its next earnings results on Tuesday, March 10th.
On average, analysts expect that Sientra will report full year earnings of ($2.57) per share for the current fiscal year, with EPS estimates ranging from ($3.01) to ($2.15). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.55) per share, with EPS estimates ranging from ($1.66) to ($1.32). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Sientra.
Sientra (NASDAQ:SIEN) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported ($0.45) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.02. The firm had revenue of $22.41 million during the quarter, compared to the consensus estimate of $20.05 million. Sientra had a negative net margin of 143.76% and a negative return on equity of 122.95%. The company’s revenue was up 32.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.72) EPS.
A number of large investors have recently modified their holdings of the business. Millennium Management LLC grew its position in Sientra by 97,855.6% in the third quarter. Millennium Management LLC now owns 3,242,332 shares of the medical instruments supplier’s stock valued at $21,010,000 after acquiring an additional 3,239,022 shares in the last quarter. UBS Group AG grew its position in Sientra by 37.9% in the second quarter. UBS Group AG now owns 2,657,863 shares of the medical instruments supplier’s stock valued at $16,372,000 after acquiring an additional 730,475 shares in the last quarter. Vanguard Group Inc. grew its position in Sientra by 64.4% in the second quarter. Vanguard Group Inc. now owns 1,857,953 shares of the medical instruments supplier’s stock valued at $11,445,000 after acquiring an additional 727,906 shares in the last quarter. BlackRock Inc. grew its position in Sientra by 11.7% in the second quarter. BlackRock Inc. now owns 1,777,741 shares of the medical instruments supplier’s stock valued at $10,950,000 after acquiring an additional 185,695 shares in the last quarter. Finally, Bamco Inc. NY grew its position in Sientra by 4.4% in the second quarter. Bamco Inc. NY now owns 1,476,000 shares of the medical instruments supplier’s stock valued at $9,092,000 after acquiring an additional 61,700 shares in the last quarter. 89.71% of the stock is owned by institutional investors.
SIEN traded up $0.30 on Thursday, reaching $8.41. 368,786 shares of the company’s stock were exchanged, compared to its average volume of 840,768. The company’s 50 day moving average is $7.75 and its 200-day moving average is $6.70. The company has a market cap of $400.79 million, a price-to-earnings ratio of -2.59 and a beta of 0.36. Sientra has a twelve month low of $4.78 and a twelve month high of $17.08. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.32 and a current ratio of 2.80.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Read More: Straddles
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.